Sandoz buys rights to Pfizer’s infliximab biosimilar in EEA
Novartis' generic pharmaceuticals division Sandoz has acquired rights of Pfizer's PF-06438179, a biosimilar of Merck's Remicade (infliximab), in the European Economic Area (EEA), to treat a range of autoimmune diseases including rheumatoid arthritis …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Autoimmune Disease | Merck | Pfizer | Pharmaceuticals | Remicade | Rheumatoid Arthritis | Rheumatology